Ex vivo activation of CD56+ immune cells that eradicate neuroblastoma

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2608-2618

  Rujkijyanont, Piya ^a   Chan, Wing Keung ^a   Eldridge, Paul W ^b   Lockey, Timothy ^a   Holladay, Martha ^a   Rooney, Barbara ^a   Davidoff, Andrew M ^c,d   Leung, Wing ^a,d   Vong, Queenie ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Therapeutic Production and Quality ^*  (United States)

^c Departments of Surgery   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CELL RECEPTOR; DNAX ACCESSORY MOLECULE 1; GRANZYME B; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NATURAL CYTOTOXICITY RECEPTOR; OKT 3; PERFORIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL ACTIVATION; CELL EXPANSION; CELL FUNCTION; CELL THERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DEGRANULATION; EX VIVO STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RISK ASSESSMENT; SURVIVAL RATE; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL CULTURE TECHNIQUES; CELL DEGRANULATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GRAFT VS HOST REACTION; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; NATURAL KILLER T-CELLS; NEUROBLASTOMA; RECEPTORS, NATURAL KILLER CELL;

EID: 84876916221     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3322     Document Type: Article

References (38)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER cancer statistics review 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2011 [cited 2012 Apr; updated Aug 2012]. Available from: Http:// seer.cancer.gov/csr/1975-2009-pops09/.
3. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-71.
4. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
5. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009; 27:289-97.
6. Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010;36:307-17.
7. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012;18:2740-53.
8. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
9. Zage PE, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer 2012; 58:1099-105.
10. Cole KA, Maris JM. New strategies in refractory and recurrent neuroblastoma: Translational opportunities to impact patient outcome. Clin Cancer Res 2012;18:2423-8.
11. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
12. Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012;30: 426-32.
13. Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, et al. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: Potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 2012;3:91.
14. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011;155:14-29.
15. Ortaldo JR, Winkler-Pickett RT, Yagita H, Young HA. Comparative studies of CD3? and CD3+CD56+ cells: Examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991;136:486-95.
16. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-9.
17. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nat Immunol 2008;9:486-94.
18. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012;12:239-52.
19. Parham P, Norman PJ, Abi-Rached L, Guethlein LA. Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond Series B Biol Sci 2012;367:800-11.
20. Murphy WJ, Parham P, Miller JS. NK cells-from bench to clinic. Biol Blood Marrow Transplant 2012;18:S2-7.
21. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 2007;97:539-42.
22. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009;15:7330-4.
23. Leung W, Iyengar R, Leimig T, Holladay MS, Houston J, Handgretinger R. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005;54:389-94.
24. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010;70:9554-61.
25. Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, et al. Blood dendritic cells suppressNKcell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:598-607.
26. Castriconi R, Dondero A, Corrias MV, Lanino E, Pende D, Moretta L, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: Critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004;64:9180-4.
27. Sivori S, Parolini S, Marcenaro E, Castriconi R, Pende D, Millo R, et al. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J Neuroimmunol 2000;107:220-5.
28. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009;114:5182-90.
29. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008;111: 3155-62.
30. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
31. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28:955-9.
32. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007;56:1733-42.
33. Kanold J, Paillard C, Tchirkov A, Lang P, Kelly A, Halle P, et al. NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. Pediatr Blood Cancer 2012;59:739-42.
34. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010;16:3901-9.
35. Altvater B, Landmeier S, Pscherer S,Temme J,Schweer K, Kailayangiri S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 2009;15:4857-66.
36. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009;69:4010-7.
37. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644-50.
38. Grupp SA, Asgharzadeh S, Yanik GA. Neuroblastoma: Issues in transplantation. Biol Blood Marrow Transplant 2012;18:S92-100.